CD39 Expression Identifies Terminally Exhausted CD8+ T Cells
Prakash Gupta(All India Institute of Medical Sciences), W. Nicholas Haining(Broad Institute), Paul Klenerman(John Radcliffe Hospital), Kristen E. Pauken(University of Pennsylvania), Simon C. Robson(Beth Israel Deaconess Medical Center), Philip Goulder(Ragon Institute of MGH, MIT and Harvard), Arlene H. Sharpe(Brigham and Women's Hospital), E. John Wherry(Parker Institute for Cancer Immunotherapy), Galit Alter(Ragon Institute of MGH, MIT and Harvard), Jernej Godec(Brigham and Women's Hospital), Wolfgang G. Junger(Beth Israel Deaconess Medical Center), Kathleen B. Yates(Broad Institute), Cormac Cosgrove(Ragon Institute of MGH, MIT and Harvard), David Wolski(Massachusetts General Hospital), Georg M. Lauer(Broad Institute), Emily Adland(Medawar Building for Pathogen Research), Carola Ledderose(Beth Israel Deaconess Medical Center)
Cited by 390
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
|The Journal of Experimental Medicine|2007|2.4k
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
|The Journal of Experimental Medicine|2009|2k